TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: Enhanced CXCL9 in autoimmune arthritis

Laboratory Investigation

Volumn 86, Issue 9, 2006, Pages 902-916

  Loos, Tamara ^a   Dekeyzer, Lies ^a   Struyf, Sofie ^a   Schutyser, Evemie ^a   Gijsbers, Klara ^a   Gouwy, Mieke ^a   Fraeyman, Annelies ^a   Put, Willy ^a   Ronsse, Isabelle ^a   Grillet, Bernard ^a,b   Opdenakker, Ghislain ^a   Damme, Jo Van ^a   Proost, Paul ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Ziekenhuis Zeeuws Vlaanderen   (Netherlands)

Author keywords

Ankylosing spondylitis; Autoimmunity; Chemokines; CXCR3; Psoriatic arthritis; Toll like receptors

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; ETANERCEPT; TOLL LIKE RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIGAND BINDING; MICROVASCULARIZATION; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHEMOKINES, CXC; CPG ISLANDS; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-1; LIGANDS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; RECEPTORS, CHEMOKINE; SYNOVIAL FLUID; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747592788     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700453     Document Type: Article

References (59)

1. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002;54:227-229.
2. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127.
3. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-686.
4. Moser B, Wolf M, Walz A, et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004;25:75-84.
5. Sallusto F, Mackay CR. Chemoattractants and their receptors in homeostasis and inflammation. Curr Opin Immunol 2004;16:724-731.
6. Sozzani S. Dendritic cell trafficking: More than just chemokines. Cytokine Growth Factor Rev 2005;16:581-592.
7. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928.
8. Proost P, Wuyts A, Van Damme J. The role of chemokines in inflammation. Int J Clin Lab Res 1996;26:211-223.
9. Strieter RM, Belperio JA, Burdick MD, et al. CXC chemokines in angiogenesis relevant to chronic fibroproliferation. Curr Drug Targets Inflamm Allergy 2005;4:23-26.
10. Struyf S, Burdick MD, Proost P, et al. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004;95:855-857.
11. Godessart N, Kunkel SL. Chemokines in autoimmune disease. Curr Opin Immunol 2001;13:670-675.
12. Strieter RM, Belperio JA, Phillips RJ, et al. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004;14:195-200.
13. Christopherson II KW, Hromas RA. Endothelial chemokines in autoimmune disease. Curr Pharm Des 2004;10:145-154.
14. Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003;9:553-566.
15. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003;273:83-101.
16. Faure E, Equils O, Sieling PA, et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 2000;275:11058-11063.
17. Li J, Ma Z, Tang ZL, et al. CpG DNA-mediated immune response in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004;287:L552-L558.
18. Maaser C, Heidemann J, von Eiff C, et al. Human intestinal microvascular endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin. J Immunol 2004;172:5056-5062.
19. Tissari J, Siren J, Meri S, et al. IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol 2005;174:4289-4294.
20. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14.
21. Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5:446-458.
22. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004;202:250-265.
23. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001;167:2887-2894.
24. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99-111.
25. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005;438:364-368.
26. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95.
27. Proost P, Vynckier AK, Mahieu F, et al. Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol 2003;33:3146-3153.
28. Proost P, Verpoest S, Van de Borne K, et al. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. J Leukoc Biol 2004;75:777-784.
29. Proost P, De Wolf-Peeters C, Conings R, et al. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J Immunol 1993;150:1000-1010.
30. Goebeler M, Yoshimura T, Toksoy A, et al. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol 1997;108:445-451.
31. Luster AD, Ravetch JV. Genomic characterization of a gamma-interferon- inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol Cell Biol 1987;7:3723-3731.
32. Yoshimura A, Lien E, Ingalls RR, et al. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999;163:1-5.
33. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752.
34. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-1103.
35. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
36. Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003;33:2987-2997.
37. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
38. Brown Z, Gerritsen ME, Carley WW, et al. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. Am J Pathol 1994;145:913-921.
39. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem 1997;272:14899-14907.
40. Tak PP. Effects of infliximab treatment on rheumatoid synovial tissue. J Rheumatol Suppl 2005;74:31-34.
41. Taylor PC, Williams RO, Feldmann M. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 2004;15:557-563.
42. Matthys P, Lories RJ, De Klerck B, et al. Dependence on interferon-gamma for the spontaneous occurrence of arthritis in DBA/1 mice. Arthritis Rheum 2003;48:2983-2988.
43. Parker LC, Whyte MK, Dower SK, et al. The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol 2005;77:886-892.
44. Underhill DM. Toll-like receptors and microbes take aim at each other. Curr Opin Immunol 2004;16:483-487.
45. Caron G, Duluc D, Fremaux I, et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005;175:1551-1557.
46. Kawai T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001;167:5887-5894.
47. Oude Nijhuis CS, Vellenga E, Daenen SM, et al. Endothelial cells are main producers of interleukin 8 through Toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients. Clin Diagn Lab Immunol 2003;10:558-563.
48. Schaefer TM, Desouza K, Fahey JV, et al. Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 2004;112:428-436.
49. Coelho AL, Hogaboam CM, Kunkel SL. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev 2005;16:553-560.
50. Gouwy M, Struyf S, Proost P, et al. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev 2005;16:561-580.
51. Cole AM, Ganz T, Liese AM, et al. Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001;167:623-627.
52. Trevani AS, Chorny A, Salamone G, et al. Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 2003;33:3164-3174.
53. Okabe Y, Kawane K, Akira S, et al. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 2005;202:1333-1339.
54. Piali L, Weber C, LaRosa G, et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 1998;28:961-972.
55. Hillyer P, Mordelet E, Flynn G, et al. Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration. Clin Exp Immunol 2003;134:431-441.
56. Kyburz D, Rethage J, Seibl R, et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003;48:642-650.
57. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001;166:7128-7135.
58. Seibl R, Birchler T, Loeliger S, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003;162:1221-1227.
59. De Rycke L, Vandooren B, Kruithof E, et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005;52:2146-2158.